A clinical trial of CTLA-4 blockade treatment for breast cancer showed that peripheral blood immune status was improved after CTLA-4 blockade in most patients, but good peripheral blood immune responses did not invariably translate into lasting beneficial outcomes [22]. The gene discussed is CTLA4; the disease is breast carcinoma.